Survivorship & Long-Term Monitoring
At a Glance
Long-term survivorship in Castleman disease involves monitoring for disease flares through blood tests like CRP and tracking symptoms like night sweats or fatigue. Patients on lifelong anti-IL-6 therapies must avoid live vaccines and maintain regular check-ups to manage infection risks.
Managing Castleman disease (CD) is often more of a marathon than a sprint. While achieving “stable disease” or “remission” is the primary goal, life after diagnosis involves a new routine of monitoring, managing treatment effects, and staying vigilant for changes in your body [1][2].
Recognizing and Monitoring a “Flare”
In Multicentric Castleman disease (MCD), the disease can cycle between periods of quiet (remission) and periods of activity, often called a flare.
- The Warning Signs: A flare is essentially your immune system “re-igniting.” You may notice the return of “flu-like” symptoms such as night sweats, unexplained fevers, or profound fatigue [3][4].
- The Biomarker “Signature”: Your doctor will use blood tests to track your C-reactive protein (CRP) and hemoglobin. For many patients, a rise in CRP is the earliest biological sign that a flare is starting, sometimes appearing before you even feel sick [5][6]. Knowing your “healthy baseline” for these markers is essential for early detection.
Life on Chronic Therapy
Many patients with iMCD remain on anti-IL-6 therapy (like siltuximab) for years, or even lifelong, to keep the disease in check.
- Long-Term Safety: Research shows that siltuximab is generally well-tolerated over long periods (up to 7 years and beyond) without evidence of “cumulative toxicity” (damage that builds up over time) [1][7].
- Managing Side Effects: While generally safe, these medications can slightly increase your risk of infections. It is important to stay current on non-live vaccinations and report any signs of illness (even a minor cold or skin infection) to your hematologist immediately [7][8].
- Crucial Vaccine Warning: If you are on immunosuppressive therapies like siltuximab or rituximab, you must strictly avoid live attenuated vaccines (such as MMR or Yellow Fever). Receiving a live vaccine while immunosuppressed can cause a severe, life-threatening infection. Always consult your hematologist before receiving any new vaccine [7].
- Chronic Fatigue: Many survivors deal with lingering fatigue even when their labs look “normal.” Managing this often requires a multidisciplinary approach, including gentle exercise and pacing your daily activities [4].
Coping with “Scanxiety”
Routine imaging (PET/CT or CT scans) is a standard part of long-term monitoring to ensure lymph nodes aren’t growing. The stress of waiting for these scans and results is often called scanxiety [9][10].
- Strategies for Peace of Mind: To manage this stress, ask your clinic to schedule your “results appointment” as close to the scan time as possible [10][11]. Focus on “present-moment” coping rather than anticipating the “what-ifs” of the results [12][13].
Your Data as a Tool: The ACCELERATE Registry
Because Castleman disease is so rare, every single patient’s experience is a vital piece of the puzzle. The ACCELERATE registry is a global database managed by the Castleman Disease Collaborative Network (CDCN) [14].
- Why it Matters: By contributing your de-identified medical records to ACCELERATE, you are helping researchers identify which treatments work best for specific subtypes. This registry has been a primary source for the current international treatment guidelines you are following today [14][15]. Participation empowers you to turn your personal journey into progress for the entire CD community.
Summary Checklist for Long-Term Health
- [ ] Know Your Baselines: Keep a record of your CRP, hemoglobin, and albumin levels when you are feeling well [5].
- [ ] Track Your “Signature” Symptoms: Note any recurring symptoms that seem to precede a flare.
- [ ] Stay Vigilant: Report any new fevers or infections immediately while on immune-modulating therapy [7].
- [ ] Contribute to Research: Join the CDCN and enroll in the ACCELERATE registry to help drive future breakthroughs [14].
Common questions in this guide
What are the warning signs of a Castleman disease flare?
Is it safe to stay on siltuximab long-term?
Can I receive vaccines while on Castleman disease therapy?
What is scanxiety and how do I manage it?
Why is it important to join the ACCELERATE registry?
Get notified when new evidence is published on Castleman disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F, Casper C, Voorhees PM, et al.
The Lancet. Haematology 2020; (7(3)):e209-e217 doi:10.1016/S2352-3026(19)30257-1.
PMID: 32027862 - 2
Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E, Sande B, Brodkin S, van Rhee F
Therapeutic advances in hematology 2022; (13()):20406207221082552 doi:10.1177/20406207221082552.
PMID: 35251585 - 3
Multicentric Castlemans disease. Symptoms, diagnostics and therapy.
Adam Z, Řehák Z, Adamová Z, et al.
Vnitrni lekarstvi 2022; (68(1)):41-53.
PMID: 35459346 - 4
The Role of Interleukin-6 in Castleman Disease.
Yoshizaki K, Murayama S, Ito H, Koga T
Hematology/oncology clinics of North America 2018; (32(1)):23-36 doi:10.1016/j.hoc.2017.09.003.
PMID: 29157617 - 5
Diagnostic and therapeutic challenges in hyaline-vascular idiopathic multicentric Castleman disease: A case report.
Lu C, Ma X, Liu B, et al.
The Journal of international medical research 2025; (53(10)):3000605251381574 doi:10.1177/03000605251381574.
PMID: 41126405 - 6
Castleman disease and TAFRO syndrome.
Masaki Y, Arita K, Sakai T, et al.
Annals of hematology 2022; (101(3)):485-490 doi:10.1007/s00277-022-04762-6.
PMID: 35044513 - 7
A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
van Rhee F, Casper C, Voorhees PM, et al.
Oncotarget 2015; (6(30)):30408-19 doi:10.18632/oncotarget.4655.
PMID: 26327301 - 8
Aseptic Meningitis-retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease.
Arakawa A, Iizuka M, Matsuda S, et al.
Internal medicine (Tokyo, Japan) 2021; (60(24)):3995-3998 doi:10.2169/internalmedicine.6938-20.
PMID: 34219105 - 9
Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.
Derry-Vick HM, Heathcote LC, Glesby N, et al.
Cancers 2023; (15(5)) doi:10.3390/cancers15051381.
PMID: 36900174 - 10
Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.
Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.
European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.
PMID: 38311702 - 11
"You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.
Derry-Vick H, Prigerson HG, Hahne J, et al.
Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.
PMID: 41338711 - 12
Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.
Dunsmore VJ, Neupert SD
Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.
PMID: 36964680 - 13
Scanxiety Conversations on Twitter: Observational Study.
Bui KT, Li Z, Dhillon HM, et al.
JMIR cancer 2023; (9()):e43609 doi:10.2196/43609.
PMID: 37074770 - 14
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F, Oksenhendler E, Srkalovic G, et al.
Blood advances 2020; (4(23)):6039-6050 doi:10.1182/bloodadvances.2020003334.
PMID: 33284946 - 15
Taking Control of Castleman Disease: Leveraging Precision Medicine Technologies to Accelerate Rare Disease Research.
Newman SK, Jayanthan RK, Mitchell GW, et al.
The Yale journal of biology and medicine 2015; (88(4)):383-8.
PMID: 26604862
This page explains long-term monitoring and survivorship for Castleman disease for educational purposes. Always consult your hematologist before making changes to your treatment or receiving vaccines.